Asset profile
CYNK-001
Cell therapy
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
CYNK-001 was Celularity's placental haematopoietic-stem-cell-derived allogeneic NK cell therapy. The AML study was terminated for 'Business reasons' and the glioblastoma study (NCT04489420) for a 'Business decision.'; the COVID-19 study was terminated for lack of enrolment and the GBM/IL-2 study withdrawn before any patient was treated. The multiple myeloma study that is this row's linked market (NCT04309084) sits at status UNKNOWN with no update since 2023, i.e. the whole program stopped. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CYNK-001: this drug | Phase 1/2 | Cell therapy | Allogeneic NK cell therapy | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Midostaurin | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | ||
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | ||
| Quizartinib | Approved | Small molecule | FLT3 | ||
| Revumenib | Approved | Small molecule | Menin | ||
| Tretinoin (Vesanoid) | Approved | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | ||
| Venetoclax | Approved | Small molecule | BCL-2 | ||
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | ||
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 | ||
| AK117 | Phase 3 | Monoclonal antibody | CD47 | ||
| APG-2575(Lisaftoclax ) | Phase 3 | Small molecule | BCL-2 | ||
| Azacitidine | Phase 3 | Small molecule | DNMT1 (DNA methyltransferase 1) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.